Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00amEST.

The registration link can be found here.

About Praxis  
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.

Investor Contact: 
Praxis Precision Medicines 
[email protected] 
857-702-9452 

Media Contact:
Dan Ferry
Life Science Advisors
[email protected]
617-430-7576

You May Also Be Interested In

• Gramercy Networks Announces New Global Ultra-Low Latency Financial Network Connecting Major Trading Hubs
• Ciro Orsini Joins Stan Lee’s LEGION OF 5 as Sergeant Saber
• Inside information: Rapala VMC Corporation issues a positive profit warning: expects full year comparable operating profit to be in the range of 12 to 14 MEUR